Compare Illumina, Inc. (ILMN) vs TKO Group Holdings Inc (TKO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Illumina, Inc. vs TKO Group Holdings Inc — how do they compare? Illumina, Inc. trades at $180.13 (market cap $27.94B), while TKO Group Holdings Inc trades at $182.49 (market cap $13.70B). The key difference: Illumina, Inc. is far larger — about 2× TKO Group Holdings Inc's market cap, and TKO Group Holdings Inc pays a 1.7% dividend while Illumina, Inc. pays none. Which is the better fit depends on your goals.
| ILMN | TKO | |
|---|---|---|
Market Cap | $27.94B | $13.70B |
Sector | Health | Technology |
52-Week High | $194.33 | $224.96 |
52-Week Low | $91.00 | $155.61 |
Enterprise Value | $29.33B | $17.88B |
Dividend Yield | — | 1.7% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Illumina (ILMN) trades at $185.36, down 0.69% on the day, with a bullish technical signal from moving averages. The stock shows strong profitability with a 19.42% net income margin and has beaten EPS estimates for three consecutive quarters. Recent news highlights expansion of the Billion Cell Atlas program and upcoming Q2 2026 earnings on July 30.
Outlook remains positive with 51% analyst buy ratings, though the current price exceeds the $178 consensus target. Key risks include competitive pressure from Roche's new sequencer and China market weakness. Earnings growth and cost control initiatives support upside potential, but valuation multiples suggest limited near-term appreciation.
TKO trades at $182.79, down 1.26% today, with a bearish technical signal despite strong analyst support. The company shows solid revenue growth with 2026 projections at $5.1B and improved net profit margin of 4.47%. Recent developments include successful international events and an $800 million share repurchase, while earnings have been mixed with Q1 2026 beating expectations but Q3 and Q4 2025 missing.
Wall Street remains bullish with 89% buy ratings and a $228.40 consensus price target, representing 25% upside potential. Key risks include execution on earnings expectations and high valuation multiples. The stock presents a growth opportunity driven by live event demand and media partnerships, though investors should monitor quarterly performance against elevated expectations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Illumina, Inc.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Read more on ILMN →About TKO Group Holdings Inc
TKO Group Holdings is a premium sports and entertainment company that serves as the parent entity for the Ultimate Fighting Championship (UFC) and World Wrestling Entertainment (WWE). Formed through a seismic merger orchestrated by Endeavor, TKO leverages a combined global fanbase of over 1 billion to drive massive revenue through media rights, global live events, and a unified sponsorship platform, effectively monopolizing the professional combat sports landscape.
Read more on TKO →
